quinoxalines has been researched along with Down Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, F; Cortez, MA; Dong, S; Jia, Z; Joshi, K; Shen, L; Snead, OC | 1 |
| Belichenko, PV; Epstein, CJ; Kleschevnikov, AM; Malenka, RC; Mobley, WC; Villar, AJ | 1 |
| Heinemann, U; Müller, W; Schuchmann, S | 1 |
3 other study(ies) available for quinoxalines and Down Syndrome
| Article | Year |
|---|---|
Kcnj6(GIRK2) trisomy is not sufficient for conferring the susceptibility to infantile spasms seen in the Ts65Dn mouse model of down syndrome.
Topics: 2-Amino-5-phosphonovalerate; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Down Syndrome; Electroencephalography; Embryo, Mammalian; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Genotype; Hippocampus; Humans; In Vitro Techniques; Infant; Membrane Potentials; Mice; Mice, Inbred C57BL; Patch-Clamp Techniques; Peptide Hydrolases; Quinoxalines; Sodium Oxybate; Spasms, Infantile; Trisomy | 2018 |
Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome.
Topics: 2-Amino-5-phosphonovalerate; Animals; Cognition Disorders; Crosses, Genetic; Dentate Gyrus; Disease Models, Animal; Down Syndrome; Evoked Potentials; Female; GABA-A Receptor Antagonists; Gene Dosage; Glycine; Hippocampus; Long-Term Potentiation; Magnesium; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Mutant Strains; Patch-Clamp Techniques; Picrotoxin; Presynaptic Terminals; Quinoxalines; Receptors, N-Methyl-D-Aspartate; Species Specificity; Trisomy | 2004 |
Altered Ca2+ signaling and mitochondrial deficiencies in hippocampal neurons of trisomy 16 mice: a model of Down's syndrome.
Topics: Aging; Alzheimer Disease; Animals; Calcium; Carcinogens; Cell Death; Cyclosporine; Diploidy; Disease Models, Animal; Down Syndrome; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Hippocampus; Karyotyping; Male; Membrane Potentials; Mice; Mice, Neurologic Mutants; Mitochondria; NADP; Neurons; Potassium; Quinoxalines; Signal Transduction; Trisomy; Vitamin E | 1998 |